EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 12
Issue: 12
Year: 2025

ROLE OF PHARMACOGENOMICS IN PERSONALIZED CANCER THERAPY

Padma Taruni Mamidisetti*[1], Batna Sai Leela Prasad[1], Sai Harshitha Lakamsani[1], Parsi Rinky Rathna Prabha[1], Pavan Karthik[1], Koppuravuri Harshitha Manasa[1], Parisapogu Rahul[1], M.S.R. Bapi Raju[2]

[1]Pharm.D Student, Department of Pharmacy Practice, Shri Vishnu College of Pharmacy, Bhimavaram, A.P, India.
padmataruni1416@gmail.com, batnaleelaprasad@gmail.com, harshithalakamsani77@gmail.com, parsis.prabha@gmail.com, pavankarthik07@gmail.com harshithak490@gmail.com, Rahulsurya4480@gmail.com
[2]Associate Professor, Department of Pharmacy Practice, Shri Vishnu College of Pharmacy, Bhimavaram, A.P, India.
bapiraju.msr@svcp.edu.in

***Corresponding Author: Padma Taruni Mamidisetti**

Pharm.D Student, Department of Pharmacy Practice, Shri Vishnu College of Pharmacy, Bhimavaram, A.P, India.

DOI: https://doi.org/10.5281/zenodo.17892689

How to cite this Article: Padma Taruni Mamidisetti*1, Batna Sai Leela Prasad1, Sai Harshitha lakamsani1, Parsi Rinky Rathna Prabha1, Pavan Karthik1, Koppuravuri Harshitha Manasa1, Parisapogu Rahul1, M.S.R. Bapi Raju2 (2025). Role Of Pharmacogenomics In Personalized Cancer Therapy. European Journal of Biomedical and Pharmaceutical Sciences, 12(12), 425–438.

Article Received on 15/11/2025 **Article Revised on 05/12/2025** **Article Published on 10/12/2025**

ABSTRACT

Pharmacogenomics, a field that investigates the impact of genetic differences on drug metabolism and efficacy, has turned over a new leaf in the treatment of cancers by making it possible to select drugs according to patient and tumor characteristics. The integration of both germline and somatic genomic data allows practitioners to select the best combinations of chemotherapy, targeted therapy, hormonal therapy, and immunotherapy to achieve maximum efficacy and least adverse effects. Major pharmacogenomic markers such as CYP2D6, UGT1A1, DPYD, EGFR, BRAF, HER2, and PD-L1 assist in determining the drug, its dosage, and the order of therapies. Notwithstanding the issues of high expense, tumor diversity and a shortage of uniform guidelines that accompany doing pharmacogenomics, the use of the aforementioned technologies ensures the future of precision oncology is bright. A pharmacogenomics-based personalized treatment has the potential to excel in clinical results, cause less suffering and lead the way toward a more routinized, patient-focused approach to cancer treatment.

KEYWORDS: Pharmacogenomics, Personalized Medicine, Cancer Therapy, Targeted Therapy, Chemotherapy, Immunotherapy, Hormonal Therapy, Biomarkers, Precision Oncology.

INTRODUCTION

Cancer is still one of the main causes of illness and death around the world, with the rising number of cases mainly due to older populations, lifestyle changes, and better detection methods. The development of better screening and treatment methods has not helped all patients, and some still have very poor outcomes due to factors like the different reactions to drugs and treatment resistance. The conventional treatment methods do not take into account patient and tumor biology differently leading to side effects, slow response to therapy, and low survival rates. The difference between the potential of therapy and the actual patient outcomes has made it very clear that precision therapy is urgently needed—this is the method that individualizes treatment based on the molecular and genetic characteristics. Precision oncology aims at the highest effectiveness, the least toxicity, and the most personalized treatment that encompasses the specific genomic makeup of both the patient and the tumor.[1,2]

Pharmacogenomics refers to the study of the impact of genetic variability on drug actions and reactions, thereby influencing the overall effectiveness of the drug and the occurrence of side effects. Genetically induced differences like SNPs, insertions, deletions, and amplifications can lead to significant changes in drug metabolism, receptor binding, activity of enzymes, and response of cells through different pathways. In cancer treatment where the agents used often have very small therapeutic windows, it is imperative to identify and understand genomic variability in order to select the

safest and most effective treatment. Pharmacogenomics is the approach that takes the patient's unique genetic profile and determines the most suitable drug for them by spotting the gene-drug interactions that are relevant in the clinic. This strategy, therefore, not only allows personalized dosing and drug selection but also aids the prediction of treatment responses, the reduction of toxicities, and the increase of overall safety in cancer management.[3,4]

Traditional chemotherapy is based on the use of cytotoxic drugs that affect a wide range of rapidly dividing cells, leading to major toxic side effects and fluctuating patient responses. This method is non-selective and therefore does not take into account the tumor's molecular heterogeneity or the genetic characteristics of the patient. Nevertheless, the last twenty years have seen a radical shift in cancer treatment due to the coming together of molecular biology, genome sequencing, and biomarker discovery. This new paradigm allows the pinpointing of specific genetic changes in the tumor, e.g. EGFR mutations in lung cancer or HER2 amplification in breast cancer, hence more accurate and effective treatments are possible. Personalized oncology combines pharmacogenomics, targeted therapy, and immunogenomics to create customized treatment plans, thereby improving clinical outcomes and minimizing the risk of toxicity compared with conventional chemotherapy.[5,6]

Genetic biomarkers are essential in selecting the right therapy for cancer patients because they allow doctors to discover specific changes in the molecules connected with drug sensitivity, resistance, or toxicity. For instance, KRAS mutations in colorectal cancer dictate the discontinuation of anti-EGFR therapy while BRCA1/2 mutations signal the use of PARP inhibitors in breast and ovarian cancer. Likewise, germline variants like UGT1A1 and TPMT affect the dosing of irinotecan and thiopurines to minimize the risk of serious side effects. The application of these biomarkers leads to a more personalized treatment plan as these molecules are matched to the tumor's biological activities and the patient's genetic disposition. The use of biomarkers in everyday clinical practice not only raises the quality of cancer treatment but also contributes to a cost-effective oncology department by eliminating the need for trial-and-error prescribing and ensuring better patient outcomes overall.[7]

FUNDAMENTALS OF PHARMACOGENOMICS

The study of Pharmacogenomics is the main scientific basis for personalized cancer therapy as it studies the impact of genetics on the individual's response to drugs against cancer. The genetic changes—either inherited (germline) or those developed in tumor cells (somatic)—are essential factors that determine not only the metabolism of the drug but also its efficacy and the likelihood of side effects. Pharmacogenomics not only sheds light on the molecular and genomic mechanisms that dictate drug pharmacokinetics and pharmacodynamics but also aids clinicians in giving up the traditional treatment approaches for more refined, custom-made therapeutic approaches. The notable genetic factors, biological pathways, and gene–drug interactions that shape the pharmacogenomic landscape in oncology are discussed in this section.[8]

Genetic Polymorphisms: SNPs, CNVs, and Mutations

Genetic polymorphisms are the major factors that determine the difference in drug response between patients. Among them, single nucleotide polymorphisms (SNPs), which are the most frequent type of genetic variation, are the most often responsible for the alteration of the protein's expression or activity. On the other hand, copy number variations (CNVs), which comprise gene deletions or duplications, are responsible for the variation of drug-metabolizing enzymes and receptor densities. Somatic mutations that are the result of tumor development over time, form unique molecular signatures that dictate the effectiveness of the respective targeted therapies. One such case is the mutations in EGFR, KRAS, or BRAF that directly determine the efficacy of their respective inhibitors. Through germline variants like TPMT, DPYD, and UGT1A1, cancer chemotherapy tolerance is also significantly influenced. To sum up, these polymorphisms provide the basis for personalized cancer treatment.[9]

Pharmacokinetics vs. Pharmacodynamics Genetic Influences

Pharmacogenomics studies the different genetic factors influencing both the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, which together determine the drug response. Variability in PK genetics influences the route of a drug through an organism: it can determine the absorption, the distribution, the metabolism, and the excretion of a drug. Drug exposure levels are mainly determined by, among others, Cytochrome P450 enzymes, transport proteins like ABCB1, and conjugating enzymes such as UGTs. Variability related to PD changes the way drugs work at their molecular targets, which may be receptors, enzymes, or even pathways involved in signaling. For instance, the mutations that change the shape of the tyrosine kinase receptors can lead or result in a lower or higher sensitivity to the cancer drugs designed to act on those receptors. The genetics of PK and PD are helpful to practitioners who can therefore give the right dose, predict the corresponding reactions and, at the same time, cause least harm.[10]

Gene–Drug Interactions: Mechanisms and Pathways

Gene-drug interactions refer to the process through which the human genome modifies the anticancer agents effects in different ways, both at the cellular and systemic levels. Such interactions can be drug activation, inactivation, transport, or binding to the molecules intended for treatment. The reduced activity of DPYD results in impaired fluoropyrimidines metabolism and,

consequently, considerable toxicity. Genetic variations in UGT1A1 lead to decreased elimination of the active metabolite of irinotecan, thereby enhancing the risk of neutropenia. Like-wise, mutations in tumor genes such as ALK or ROS1 also influence the level of response to tyrosine kinase inhibitors. Understanding these interactions enables health professionals to identify the specific patients who will get the most out of certain treatments, and those who need their doses adjusted or who should be given alternative therapies.[11]

Tumor Genomics vs. Germline Genomics in Therapy Selection

Pharmacogenomics consists of two separate but allied areas: tumor genomics and germline genomics. Tumor genomics looks at somatic mutations found in tumor cells and considers them either therapeutic targets or drug resistance markers. Biomarkers like ALK rearrangements, HER2 amplification, and BRAF mutations help in the precise selection of targeted therapies. Germline genomics studies genetic variants that are passed on from parents to children and that are capable of either speeding up or slowing down the effects of drug metabolism or causing the patient to be susceptible to the side effects of the drugs. For example, people with TPMT or NUDT15 deficits risk severe myelosuppression if treated with thiopurines. Merging the tumor and germline genomic data forms a holistic picture of individualized therapy, thereby maximizing therapeutic gain and minimizing safety risks.[12]

TECHNOLOGIES USED IN PHARMACOGENOMIC ANALYSIS

1. Next-Generation Sequencing (NGS)

NGS allows for the simultaneous high-throughput sequencing of multiple genes and hence rapid identification of somatic and germline mutations, CNVs, and indels, all of which are important in cancer therapy. It also offers great advantages in terms of deep coverage, high accuracy, and scalability, which make it suitable for not only personalized oncology and targeted gene panels but also monitoring the evolution of the tumor through repeated genomic profiling.

2. Whole Genome Sequencing (WGS)

WGS takes the whole genomic sequence and that way it can detect all genetic variations such as SNPs, structural changes, CNVs, or even mutations in regulatory regions. As a result, it can give the full picture of the tumor and the germline genomic architecture. While being a pricey method, WGS still allows the shedding of light on the existence of new biomarkers and supplying an ample amount of data for making precision cancer therapy decisions.[13]

3. Whole Exome Sequencing (WES)

WES methodology is devoted to sequencing the exons of the genes which translate into proteins, and where most of the clinically relevant variants are found. WES gives the ability to detect mutations relevant for medical treatment with the best quality over WGS. WES allows the detection of driving mutations, genetic variants that indicate risk of inheriting, and the principal pharmacogenomic markers that have a say on the corresponding drug's efficiency, toxicity, and adaptations of the treatment of the patient in the case of oncology.

4. Microarray-Based Genotyping

Microarrays discover thousands of predefined SNPs and known genetic variants all at once. Even though this method is limited to known markers, it is still cost-effective for large-group pharmacogenomic testing. Clinically, Microarrays are often employed to uncover germline mutations that are responsible for changes in drug metabolism, the patient’s risk of experiencing side effects, and the effectiveness of the drug used thus facilitating large-scale customized treatment.[14]

5. RNA Sequencing (RNA-seq)

RNA-seq not only quantifies gene expression but also classifies splicing isoforms and uncovers fusion transcripts like ALK or ROS1. It acts as a tool that sheds light on the changes at the molecular level that are not really responding to the drugs. In revealing not only the pathways that are being encouraged by mutations but also the mechanisms related to drug resistance, RNA-seq extends the power of DNA sequencing to the area of treatment selection and monitoring in precision oncology.

6. Digital PCR (dPCR)

Digital PCR, which is also known as dPCR, allows for the detection of low-frequency mutations in the case of liquid biopsy and also offers real-time monitoring of treatment with the ability to track minor resistant mutations. The technique's ability to simultaneously partition samples into thousands of reactions leads to the precise quantification of particular genetic variants which is referred to as Digital PCR.

7. Quantitative PCR (qPCR)

The method, qPCR, which is also known as quantitative PCR enhances the amount of DNA in a very specific way and quantifies the DNA that the PCR has amplified. The technique provides very rapid and sensitive results and it is mainly used in detecting and identifying the specific mutations that can be targeted such as EGFR, BRAF, or KRAS. Its excellent sensitivity, rapidity, and affordability establish it as the best choice for routine clinical diagnostics, particularly when patients suffering from cancer are evaluated for single-gene pharmacogenomics.[15]

PHARMACOGENOMICS AND CANCER BIOLOGY

Cancer is majorly a genetic disorder through which the normal cell growth and survival are altered by the mutations, chromosomal abnormalities, and epigenetic changes. The changes on the genomic level are responsible for the activation of oncogenes, the tumor

suppressor genes' inactivation, and the disruption of the key pathways that regulate proliferation, apoptosis, and DNA repair. The field of pharmacogenomics observes this molecular mismatching more closely to get the picture of cancers' origins, tumor characteristics, and the most relevant therapeutic targets. In this way, pharmacogenomics not only connects genetic defects to the cancer biology but also gives the basis for personalized cancer treatment.

The mutations in cell signaling pathways that include MAPK, PI3K/AKT, JAK/STAT, and DNA repair all lead to fast tumor growth but also the characteristics of drug response. For instance, lung cancers with EGFR mutations are treated with tyrosine kinase inhibitors and they respond very well while tumors with KRAS mutations resist the treatment. Pharmacogenomics assists in pinpointing these mutations related to the specific pathways and forecasts which drugs will be effective or not. This molecular comprehension links cancer biology and therapy choice together, making it certain that the treatments precisely target the genomic defects that are causing tumor growth.[16]

Tumor heterogeneity is the result of the presence of different genetic make-ups among cancer cells in the same tumor which is a very common phenomenon. The differences between the cells in the tumor cause the tumor to have different responses to the treatment and at the same time, some of the cells are able to survive and evolve under the pressure of the treatment. Pharmacogenomic profiling captures these dynamic genomic changes, which in turn helps to identify resistant clones and to modify therapies accordingly. It is very important to understand how cancer biology changes over time in order to improve long-term treatment success and to conquer drug resistance.

Pharmacogenomics has been integrated into cancer biology and this has resulted in a significant change in the clinical approach to oncology. Genomic information is used for drug selection, dosing, toxicity prediction, and therapy monitoring. The biomarkers BRCA1/2, PD-L1 expression, TMB, and ALK or BRAF mutations have enabled highly targeted treatments and immunotherapies that are specifically designed for the patient's cancer. The alignment of genetic data with biological behavior enhances treatment precision, minimizes adverse effects, and significantly improves survival rates, thus, marking a major progress in modern oncology.[17]

ROLE OF PHARMACOGENOMICS IN CANCER TREATMENT

1. Personalizing Chemotherapy: Individual genetic profiles are the basis of pharmacogenomics that plays a significant role in the customization of chemotherapy. The differences in metabolism of drugs through enzymes like CYP450, UGT1A1, DPYD, and TPMT determine the drug's efficacy, declaration, and toxicity. A case in point is the patients with UGT1A1*28 polymorphism who are more prone to neutropenia caused by irinotecan, while those with the DPYD variant might suffer from severe toxicity from the drug 5-FU. The detection of these genetic variations allows the doctors to choose the drug and the dose that are just right for the patient, so that the side effects are minimized and healing is maximized.[18]

2. Guiding Targeted Therapy: Targeted cancer therapies are based on the presence of specific molecular changes in the affected cells. Pharmacogenomic profiling uncovers the mutations that can be targeted, for example, in case of the Epidermal Growth Factor Receptor (EGFR), Breast Cancer gene (BRAF), Hormone Receptor (HER2), Anaplastic Lymphoma Kinase (ALK), ROS proto-oncogene 1 (ROS1), and Neurotrophic Tyrosine Receptor Kinase (NTRK) fusions, also directing the use of tyrosine kinase inhibitors, monoclonal antibodies, and fusion-targeted agents. Therefore, the use of such an approach maximizes the response rates, prolongs the period before resistance develops, and increases the chances of survival when compared to conventional methods since the treatment is done in accordance with tumor biology.[19]

3. Enhancing Immunotherapy: Pharmacogenomics dominates immunotherapy choices by pinpointing the exact predictive biomarkers like PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI). These biomarkers are the ones that allow to foresee the patients that will get the benefit of checkpoint inhibitors, such as pembrolizumab and nivolumab, and at the same time, cut off the non-responders from being unnecessarily exposed. The application of genomic insights assures the immuno-therapy to be effective and safe thus contributing to personalized oncology strategies.

4. Predicting and Overcoming Drug Resistance: It is a fact that cancer cells may still find ways to become non-sensitive to the drug, e.g., by gaining secondary mutations or changing the pathway. On the plus side, pharmacogenomics can pinpoint the very resistance mutations, such as EGFR T790M in lung cancer or BCR-ABL T315I in leukemia, thus making it possible to switch therapies in no time. By monitoring the evolution of the tumor through circulating tumor DNA (ctDNA) the doctors can make real-time modifications that will ensure that the therapy remains effective and the disease does not progress.[20]

5. Improving Safety and Reducing Toxicity: Pharmacogenomic testing does not only identify patients who are likely to suffer from drug toxicity but also reduces the number of negative events. Genetic information about the metabolism of medications by the body, the transport of drugs, and the repair of DNA in tumors allows for the adjustment of the drug amount to be given, for the treatment to be safer, and for the patient to be more compliant. Consequently, this results in fewer

hospitalizations, no interruption of treatment, and better quality of cancer care.

6. Facilitating Precision Clinical Trials and Drug Development: Pharmacogenomics indicates the way of conducting clinical trials by distinguishing patient groups that are most likely to respond to new therapies. Biomarker-based participant stratification not only improves but also quickens the approval of new drugs. This method guarantees that the new drugs are evaluated in the most applicable populations, thus making the precision oncology movement and the delivery of personalized treatment to patients faster.[21]

PHARMACOGENOMICS IN CANCER: MECHANISMS

1. Genetic Variations Affecting Drug Metabolism: The first way that pharmacogenomics affects cancer treatment is by changing the activity of drug-metabolizing enzymes. The polymorphisms in the genes that code for phase I enzymes (CYP450 family) and phase II enzymes (UGT1A1, TPMT, DPYD) change drug activation, detoxification, and elimination. For instance, UGT1A1*28 reduces the glucuronidation of irinotecan metabolites, thus increasing toxicity. These variations in genotype are the reason for the interpatient differences in drug efficacy and side effects, which, in turn, depend on the basis of dose adjustments and personalized chemotherapy.[22]

2. Alterations in Drug Targets: The genetic mutations that occur in oncogenes, tumor suppressor genes, or signaling pathway components may cause a change in the binding affinity or the effectiveness of the anticancer drugs. The mutations of the EGFR gene in NSCLC lead to the increase of the sensitivity of the tumor to the tyrosine kinase inhibitors, while the BRAF V600E mutations are pulling the MAPK pathway to grow and become more responsive to BRAF inhibitors. On the other hand, secondary mutations like EGFR T790M, can grant drug resistance. Knowing these target-based mechanisms allows precision in the selection of targeted therapies.

3. Transporter-Mediated Drug Disposition: Transport proteins play a major role in determining the amount of drug intracellularly by controlling its uptake and elimination. ABC transporters (ABCB1, ABCG2) are responsible for pumping out chemotherapeutic drugs from the cells of the tumor, thus it is one of the reasons for the development of the multidrug resistance, while solute carriers (SLC22A1, SLCO1B1) determine the absorption of drugs and their distribution in the tissues. The genetic variations in these transporters can modify the pharmacokinetics and the patient's response to treatment, therefore the need for transporter profiling in personalized oncology is marked as a crucial step.[23]

4. DNA Repair and Resistance Mechanisms: Genetic variations in the DNA repair genes, such as BRCA1/2, ERCC1, and MMR, directly influence both tumor sensitivity to and resistance against DNA-damaging agents used in therapy. Radioresistant tumors would stop doing so because they are oxidized, whereas homologous recombination proficient cancerous cells would enjoy chemotherapy with platinum resistance due to proficient repair. Pharmacogenomics analyzes DNA repair pathways and predicts treatment responsive and rational drug selection.

5. Epigenetic Modifications and Gene Expression: Epigenetic alteration of the DNA molecule may be available through cytosine residue methylation or histone acetylation or deacetylation, but it influences drug action. Genetic changes that unfavorably methylate or poorly suppress tumorigenic genes or increasingly activate drug-inactivating metabolic enzymes can make cancer drugs less effective. Merging the profiling of epigenome with that of pharmacogenes provides a complete mechanism-based variancy understanding in the patients' response to cancer treatment.

6. Immune-Related Genetic Mechanisms: Drug resistance caused by the pharmacogenomics of the immune system is also one of the side effects of the genetic polymorphism affecting the immune checkpoints, neoantigen presentation, and cytokine pathways. The PD-L1 level, TMB, and MSI together reflect the genetic basis behind the efficacy of immune checkpoint blockers. Monitoring these markers will provide information on the likelihood of benefiting from immunotherapy or not.[24]

MAJOR PHARMACOGENOMIC BIOMARKERS IN CANCER THERAPY

EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)

Mutations in the epidermal growth factor receptor (EGFR), especially deletions in exon 19 and the L858R mutation in exon 21, are the most important predictive biomarkers in non-small cell lung cancer (NSCLC). These mutations, which activate the receptor, lead to an unstoppable cell division process, but at the same time, the cancer becomes very responsive to the EGFR tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, and osimertinib. The mutation testing of the EGFR gene determines the drugs to be used for the first-line therapy, whereas the T790M resistance mutation indicates the use of a second- or third-generation TKI, which allows for a customized treatment plan that not only increases the response rates but also prolongs the survival of patients.[25]

KRAS and NRAS Mutations in Colorectal and Lung Cancer

Mutations in the RAS and NRAS genes are factors that predict of poor response to treatment with anti-EGFR monoclonal antibodies, including cetuximab and panitumumab. The mutations such as KRAS G12D, G13D, and NRAS Q61H lead to activation of the signal transduction pathways of MAPK and PI3K, and

therefore, the regulators of the pathway therapy become ineffective. The identification of these mutations in colorectal and lung cancer allows the healthcare provider to avoid inappropriate drug use, select alternative medications or combinations of targeted and chemotherapy, and determine the patient's prognosis, thus highlighting their importance in precision medicine.

BRAF Mutations in Melanoma and Other Solid Tumors

A BRAF V600E mutation causes the misspecified MAPK pathway to be amplified and is a major predictive biomarker for melanoma, colorectal, and thyroid cancers. Such tumors can be treated quite effectively with BRAF inhibitors (vemurafenib, dabrafenib) sometimes used in conjunction with MEK inhibitors to combat resistance. The BRAF mutation testing facilitates the selection of patients for targeted therapy, the optimization of combination regimens, and the increase of overall patient survival, thereby illustrating that pharmacogenomic profiling has a direct impact on therapeutic decision-making.[26]

HER2 Amplification in Breast and Gastric Cancer

The overexpression or amplification of the HER2 gene is a very important indicator in both breast and stomach cancers. HER2-positive tumors are, on the one hand, very aggressive, but on the other hand, they will respond very well to the targeted agents like trastuzumab, pertuzumab, lapatinib, and trastuzumab emtansine (T-DM1) because of this. The HER2 status test helps to choose the correct treatment and the right amount of it, thus keeping the chances of progression-free survival high and the risk of recurrence low. Adding HER2 testing to clinical practice is one of the most successful instances of precision medicine in solid tumors.

BRCA1/2 Mutations and Homologous Recombination Deficiency (HRD)

The mutations of the BRCA1/2 genes, whether germline or somatic, cause the homologous recombination repair to fail, thus increasing the base pair errors and making the cells vulnerable to the PARP inhibitors such as olaparib, niraparib, and talazoparib. These markers are especially important in breast, ovarian, pancreatic, and prostate cancers because they not only allow the use of targeted therapy but also the assessment of hereditary cancer risk. The HRD scoring system increases the role of BRCA testing in the identification of tumors that are susceptible to DNA damage response-targeted therapies.[27]

PD-L1 Expression in Immunotherapy

The expression of Programmed death-ligand 1 (PD-L1) is one of the most important factors used to determine whether the patient will respond well to immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab. PD-L1 expression is positively associated with immune activation and thus with response rates in the case of lung, bladder, and head-and-neck cancers. Even though PD-L1 does not give a hundred percent accurate results, its testing still plays an important role in choosing the right immunotherapy, combining the right drugs, and the right dosage, making it indispensable in precision immuno-oncology.

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR)

The defective DNA repair process in the case of tumors with MSI-H and dMMR leads to the gradual accumulation of mutations which create new antigens and thus increase immunogenicity. Besides, these biomarkers are among the most reliable predictors of the response to PD-1/PD-L1 inhibitors where the FDA has approved pembrolizumab for tissue-agnostic MSI-H/dMMR tumors. The testing of MSI and dMMR is of utmost importance in colorectal, endometrial, and gastric cancers, as it facilitates the utilization of personalized immunotherapy strategies and also the enhancement of the treatment of patients who are resistant to traditional therapies.

ALK, ROS1, and NTRK Gene Rearrangements

Oncogenic gene fusions of the types ALK, ROS1, and NTRK indicate a very high probability of the tumor responding to the specific targeted drugs. The drugs responding to ALK rearrangements are crizotinib, alectinib, and lorlatinib; crizotinib and entrectinib are for ROS1 fusions; NTRK fusions are treated with larotrectinib or entrectinib. The detection of such fusions permits the application of targeted therapy over a variety of tumor types, which often results in quick and long-lasting responses, even in the case of advanced disease.[28]

UGT1A1, DPYD, and TPMT as Pharmacogenomic Toxicity Biomarkers

The UGT1A1, DPYD, and TPMT gene alterations are the indicators for chemotherapy-induced toxicity. UGT1A1*28 predicts the risk of developing neutropenia with irinotecan treatment; DPYD mutations enhance the toxicity of 5-FU and capecitabine; and TPMT deficiency brings about severe myelosuppression induced by thiopurines. The genetic testing of these genes empowers the doctors to customize the dosing of the drugs, avoid potentially fatal side effects, and safely manage the chemotherapy regimens in cancer patients.

Tumor Mutational Burden (TMB)

Tumor mutational burden quantifies the number of somatic mutations per tumor genome and serves as a predictive biomarker for immunotherapy. High TMB increases neoantigen load, enhancing immune recognition and response to checkpoint inhibitors. TMB assessment in lung cancer, melanoma, and other solid tumors guides immunotherapy decisions, helping select patients most likely to benefit from PD-1/PD-L1 blockade, and represents an emerging tool in precision oncology.[29]

PERSONALIZED MEDICINE

Personalized medicine, or precision oncology in other words, is a process of customizing a patient's cancer treatment based on his or her genetic makeup, tumor properties, and pharmacogenomic data. What is more, the molecular insights originally applied to the patient's characteristics are used to optimize drug selection, dosing, and combinations, while traditional therapy with a standard approach would be ruining efficacy with high toxicity. This shift in the direction of the patient's needs at the center of the process leads to the elimination of toxicity alongside the maximization of efficacy and the improvement of overall survival that represents a new age in the treatment of cancers.

Role in Chemotherapy

Chemotherapy is still one of the main methods used to treat cancer, but the difference in drug response and toxicity between patients often is the reason their efficacy is limited. Drug interaction through pharmacogenomics can help to personalize the chemotherapy regimens as it deals with the study of genetic differences revealing the metabolism, transport characteristics, and cellular receptors of drugs. The application of pharmacogenomics to chemotherapy allows for the formation of individualized regimens that entail less toxicity and the same efficacy. Genetic testing that is done before therapy helps dictate the choice of drug, the adjustment of dosage, and the combination strategies. Personalized chemotherapy not only leads to improved treatment adherence but also to a decrease in hospital stays due to adverse effects and an overall enhancement in patient outcomes, thus being a manifestation of the principles of precision oncology.[30,31]

Gene / Biomarker	Chemotherapy Drug	Cancer Type	Clinical Relevance / Toxicity
UGT1A1*28	Irinotecan	Colorectal, Lung	Reduced glucuronidation increases risk of neutropenia and diarrhea; dose adjustment recommended
DPYD	5-Fluorouracil (5-FU), Capecitabine	Colorectal, GI	Deficient enzyme activity causes severe toxicity (myelosuppression, mucositis); testing guides dose reduction
TPMT	Thiopurines (Mercaptopurine, Azathioprine)	Leukemia	Low TPMT activity increases risk of myelosuppression; genotype-guided dosing prevents toxicity
CYP2D6	Tamoxifen	Breast	Poor metabolizers have reduced conversion to active metabolite (endoxifen), leading to lower efficacy
CYP2C8 / CYP3A4	Paclitaxel	Breast, Ovarian, Lung	Genetic variations affect metabolism, influencing toxicity (neutropenia, neuropathy) and therapeutic response
ERCC1	Platinum-based drugs (Cisplatin, Oxaliplatin)	Lung, Colorectal	High expression predicts resistance; low expression predicts better response due to impaired DNA repair
XRCC1	Alkylating agents, Platinum compounds	Various	Polymorphisms affect DNA repair; certain variants increase toxicity risk or reduce efficacy
ABCB1 (P-gp)	Doxorubicin, Vincristine	Various	Efflux transporter polymorphisms alter intracellular drug levels, affecting resistance and toxicity

Role in Targeted Therapy

The method of cancer therapy is such that it is aimed only at the very few molecular pathways that are responsible for the tumor's growth and existence. The use of pharmacogenomics is very crucial as it points out the exact genetic changes in the tumors, for instance, mutations, amplifications, or fusions, that are likely to respond to the targeted agents. If one mix pharmacogenomics with targeted cancer therapy, one would have the possibility of getting the right drugs, the right doses, and the right order for the patient. Discovering the mutations that can be worked on, doctors can make therapy more efficient, predict the development of resistance, and check the progress of treatment. The guiding of pharmacogenomic therapy in targeted fashion signifies the peak of precision oncology, extending life and minimizing side effects.[32,33]

Biomarker / Gene	Cancer Type	Targeted Therapy / Drug	Clinical Relevance
EGFR (Exon 19 deletion, L858R)	NSCLC	Gefitinib, Erlotinib, Osimertinib	Predicts sensitivity to EGFR-TKIs; T790M mutation indicates resistance to first-generation TKIs, guiding next-generation inhibitors
BRAF V600E	Melanoma, Colorectal,	Vemurafenib, Dabrafenib ± MEK inhibitors	Activating mutation predicts response to BRAF inhibitors; combination with MEK inhibitors

	NSCLC		improves efficacy and delays resistance
HER2 amplification	Breast, Gastric	Trastuzumab, Pertuzumab, Lapatinib, T-DM1	Predicts response to HER2-targeted therapy; guides therapy selection and improves survival
ALK fusion	NSCLC	Crizotinib, Alectinib, Ceritinib	ALK rearrangements confer sensitivity to ALK inhibitors; resistance mutations guide therapy sequencing
ROS1 fusion	NSCLC	Crizotinib, Entrectinib	Predicts sensitivity to ROS1 inhibitors; enables precision therapy for rare fusion-positive patients
NTRK fusion	Multiple solid tumors	Larotrectinib, Entrectinib	Oncogenic fusions respond to NTRK inhibitors regardless of tumor origin; enables tumor-agnostic targeted therapy
BRCA1/2 mutations / HRD	Breast, Ovarian, Prostate, Pancreatic	PARP inhibitors (Olaparib, Niraparib, Talazoparib)	Defective DNA repair pathways predict sensitivity to PARP inhibitors; allows synthetic lethality-based therapy
PD-L1 expression / TMB / MSI	Multiple tumors	Pembrolizumab, Nivolumab, Atezolizumab	Predictive biomarkers for immune checkpoint inhibitors; high expression or MSI-high/TMB-high tumors respond better to immunotherapy

Role in Immunotherapy

Immunotherapy has revolutionized the treatment of cancer by utilizing the patient's immune system to destroy the tumor cells. On the other hand, pharmacogenomics is crucial in determining which patients are most likely to benefit from immune-based therapies, as well as in predicting potential resistance or immune-related side effects. In this regard, pharmacogenomics in immunotherapy assists precision oncology by providing information on therapy selection, dosing, and combination strategies. The integration with chemotherapy, targeted therapy, and other modalities allows for adaptive treatment plans that are in line with the changing genomic and immunologic profiles. Such a patient-centered approach ensures that the maximum response is achieved, the adverse events are reduced, and it marked the future of personalized cancer care.[34,35]

Biomarker / Gene	Cancer Type	Immunotherapy / Drug	Clinical Relevance
PD-L1 expression	NSCLC, Melanoma, Bladder, Head & Neck	Pembrolizumab, Nivolumab, Atezolizumab	High PD-L1 expression predicts better response to PD-1/PD-L1 inhibitors; guides patient selection for therapy
Tumor Mutational Burden (TMB)	Multiple solid tumors	Pembrolizumab, Nivolumab	High TMB tumors generate more neoantigens, enhancing immune recognition and response to checkpoint inhibitors
Microsatellite Instability (MSI) / Mismatch Repair Deficiency (dMMR)	Colorectal, Gastric, Endometrial	Pembrolizumab, Nivolumab	MSI-high or dMMR tumors show high immunogenicity, predicting favorable response to checkpoint blockade
HLA Genotype	Multiple tumors	Immune checkpoint inhibitors	Certain HLA alleles influence antigen presentation and immune response, affecting efficacy and risk of immune-related adverse events
B2M Mutations	Melanoma, NSCLC	Checkpoint inhibitors	Loss-of-function mutations impair antigen presentation, leading to primary resistance to immunotherapy
JAK1 / JAK2 Mutations	Melanoma, NSCLC	PD-1 inhibitors	Mutations in interferon signaling pathways can confer resistance, predicting lack of response to therapy
Neoantigen Load	Multiple tumors	Immune checkpoint inhibitors	Higher neoantigen burden increases immunogenicity, improving likelihood of response to immunotherapy
T-cell Receptor (TCR) Diversity	Solid tumors	Adoptive T-cell therapy	Greater TCR diversity correlates with stronger immune response and improved efficacy of T-cell-based therapies

Role in Hormonal Therapy

Hormone therapy is a very important part of the treatment for hormone-dependent cancers, especially for breast and prostate cancers. Pharmacogenomics is the study that looks at the genetic differences between people and how they influence the metabolism of drugs, as well as the expression of receptors and the activation of signaling pathways, so that then they receive the right hormonal therapy. Customizing the treatment according to the patient's genetic makeup can not only increase the effectiveness, but also reduce the side effects, and thus improve the overall outcome in cancers that are sensitive to hormones. By utilizing the genetic information from pharmacogenomics, the clinician can make the best decision regarding the drug to be used, its dosage, and the order of administration. Customized hormone therapy leads to less toxicity, better compliance, and higher clinical advantage. This strategy along with tumor molecular profiling is the hallmark of precision oncology and improves treatment results in cancers dependent on hormones.[36,37]

Gene / Biomarker	Hormonal Therapy Drug	Cancer Type	Clinical Relevance / Impact
CYP2D6	Tamoxifen	ER+ Breast Cancer	Poor metabolizers produce lower levels of endoxifen, reducing efficacy and increasing recurrence risk; genotype-guided dosing improves outcomes
CYP19A1	Aromatase inhibitors (Anastrozole, Letrozole, Exemestane)	ER+ Breast Cancer	Polymorphisms affect aromatase activity, influencing drug metabolism and response; guides therapy selection and dosing
ESR1 (Estrogen Receptor)	Tamoxifen, Aromatase inhibitors	ER+ Breast Cancer	Mutations or variants can confer resistance to therapy; monitoring helps in therapy adjustment and combination strategies
AR (Androgen Receptor)	Bicalutamide, Enzalutamide, Abiraterone	Prostate Cancer	Polymorphisms and splice variants affect receptor sensitivity; predict response to androgen deprivation therapy (ADT) and anti-androgen drugs
CYP17A1	Abiraterone	Prostate Cancer	Variants influence androgen biosynthesis and drug response; pharmacogenomic profiling guides therapy personalization
SRD5A2	Finasteride, Dutasteride	Prostate Cancer	Genetic variations impact androgen metabolism and ADT efficacy; may guide dose selection or alternative therapy
HSD3B1	Androgen deprivation therapy agents	Prostate Cancer	Polymorphisms affect steroid hormone synthesis; associated with therapy resistance and progression risk

IMPORTANCE OF PERSONALIZED MEDICINE IN ONCOLOGY

1. Enhancing Treatment Efficacy

Personalized medicine allows doctors to customize the cancer treatment according to the genetic makeup of the patient's tumor, their pharmacogenomic profile, and the molecular biomarkers. The efficacy of treatment using such drug combinations that specifically target tumor drivers, including EGFR, BRAF, HER2, or ALK alterations, is so much higher than with standard regimens. Precision oncology is represented by the area of treatment that patients receive which is most likely to lead to tumor regression, durable responses, improved progression-free and overall survival, thus.

2. Minimizing Toxicity and Adverse Effects

To be more specific, conventional cancer treatment would often subject cancer patients to high toxicity owing to the lack of individualized dosing, and personalization of medicine utilizes pharmacogenomic insights to foresee the drug metabolism and tolerance, thus enabling clinicians to vary the drug selection and dosage. For instance, UGT1A1*28 and DPYD variants are indicators of chemotherapy toxicity and TPMT deficiency determines the safety of thiopurines. With fewer side effects, patients are more likely to stick to their treatment plans, hospital stays are shorter, and the patients who are undergoing therapy will have a better quality of life.[38]

3. Optimizing Use of Targeted Therapy and Immunotherapy

Personalized medicine uncovers actionable mutations, gene fusions, and immunogenomic markers which thereby steer the ways of using targeted therapy and immunotherapy. PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) give a forecast of the treatment by immune checkpoint inhibitors while HER2 amplification, ALK, and ROS1 fusions are the factors for the selection of the drugs targeting the specific site. This method guarantees that treatments are given to the patients who are most likely to benefit, thus the ineffective ones are put aside, and the clinical outcomes are also maximized.

4. Predicting Resistance and Monitoring Disease

Genomic profiling in personalized oncology provides an early alert of the potential drug resistance mechanisms that might be developed, an example of which is EGFR T790M or BCR-ABL T315I mutations. Liquid biopsy

which is a method of detecting circulating tumor DNA (ctDNA) gives the opportunity of real-time monitoring of the tumor evolution, thus therapy adjustment is possible before the clinical relapse occurs. This preventive method contributes to the controlling of the disease for a longer period and also avoids the patients from being subjected to ineffective drugs for no reason.

5. Guiding Risk Assessment and Preventive Strategies
Personalized medicine does not end at treatment but it also helps in predicting the risk of cancer. Germline mutations in BRCA1/2, TP53, and PALB2 are the ones that point to high-risk individuals whose treatments may involve early surveillance, prophylactic interventions, or chemoprevention. This proactive risk management assists in cutting down the incidence of cancer and making it possible to have early intervention, thus improving patient outcomes and contributing to the shaping of preventive oncology strategies.[39]

APPLICATIONS OF PHARMACOGENOMICS IN CANCER

1. Personalized Chemotherapy Selection.
The use of pharmacogenomics enables the clinicians to choose the chemotherapy drugs that are the most suitable for the particular patient based on the patient's genetic makeup. Genetic variations in enzymes responsible for drug metabolism, transporters, and prodrug-activating genes can predict drug responses and side effects. For example, UGT1A1*28 indicates a high risk of getting neutropenia due to irinotecan treatment, and the presence of DPYD mutations affects the severity of the side effects caused by 5-FU. This accurate method of treatment selection helps to avoid side effects and also makes the patient more responsive to the treatment.

2. Targeted Therapy Optimization
The genomic profiling process detects mutations, amplifications, and fusions that are actionable and at the same time available for targeted therapy. These mutations include EGFR, BRAF, HER2, ALK, ROS1, and NTRK, thus enabling the selection of the targeted therapy. The pairing of drugs with specific molecular drivers through pharmacogenomics not only increases response rates and defeats resistance but also prolongs the patient's life, effectively making the treatment process more personalized and effective.[40]

3. Immunotherapy Guidance
Pharmacogenomics aids in the selection of patients for immunotherapy treatment by measuring biomarkers like PD-L1 expression, the tumor's mutational burden (TMB), and microsatellite instability (MSI). These factors can help predict the responsiveness of patients to immune checkpoint inhibitors such as pembrolizumab and nivolumab. The inclusion of patients based on their genetic makeup not only increases the effectiveness of the treatment but also prevents the patients from exposure to the treatment that will not work for them and lowers the risk of immune-related toxicity in those classified as non-responders.

4. Risk Prediction and Cancer Prevention
Germline mutations in BRCA1/2, TP53, and PALB2 suggest an increased risk for some cancers. The use of pharmacogenomic testing allows for the patient's risk to be determined, the patient to be monitored closely, and the application of preventive measures like prophylactic surgery or chemoprevention. The personalized risk assessment constitutes a support for preventive oncology where the long-term outcomes get improved, and cancer incidence among high-risk individuals gets reduced.[41]

5. Dose Optimization and Toxicity Management
Drug metabolism, efficacy, and adverse effects are influenced by the genetic variations in ADME genes and drug targets. The pharmacogenomic approach will allow the adjustment of drug dosages such that toxicities are minimized, and these will include cardiotoxicity, myelosuppression, and mucositis, all the while the drug's therapeutic activity is also maintained. The outcome of this would be treatment adherence improved, hospitalizations reduced, and the patient's quality of life overall enhanced.

6. Monitoring and Predicting Drug Resistance
The use of pharmacogenomics provides the opportunity for the real-time monitoring of tumor evolution via circulating tumor DNA (ctDNA) and secondary mutations. The detection of resistance mutations, such as EGFR T790M or BCR-ABL T315I, will alert the oncologists who will then switch treatment to the next generation of inhibitors in time. The early detection of resistance leads to the sustained control of the disease and consequently better survival rates in the long run.[42]

7. Clinical Trial Stratification
With the use of genomic profiling, it is possible to identify the patient subgroups that would respond best to the new experimental therapies. Pharmacogenomics-based patient stratification is one of the most effective ways to optimize the clinical trial process, reduce the number of failed trials, and shorten the time required for precision medicines to receive regulatory approval. The implementation of this method opens up the testing of newly developed treatments to the patient groups that are most appropriate, thereby improving the clinical relevance and raising the success rates.

8. Combination Therapy Design
Pharmacogenomics is one of the major factors in obtaining the rational combination therapies' designing by indicating the pathways that are co-operating and predicting the occurrence of synergistic effects. An instance of this is the simultaneous treatment of PARP inhibitors and DNA-damaging agents in BRCA-mutated tumors to cause a stronger effect. The genetic information directs one away from the combination of drugs that will act against each other and thus lead to

overlapping toxicities, hence the therapeutic benefit can be given to the patients in full.[43]

9. Real-Time Adaptive Therapy
Continuous pharmacogenomic monitoring allows for adjusting the treatment according to the evolution of tumor genetics. The oncologists who perform liquid biopsy and genomic sequencing can modify the choice of drug, its dose, or the combination of drugs completely in real-time. This dynamic, patient-specific approach not only maximizes treatment response but also delays tumor progression and is a true demonstration of precision oncology

10. Enhancing Drug Development and Regulatory Approval
Pharmacogenomics quickens the process of drug development by recognizing biomarkers that foretell the impact and harm in the initial-stage tests. The regulation establishments demand more and more biomarker-based classification to give their approval to the targeted therapies. This use is certain that medicines will be delivered to the proper patients at an early stage, thereby lowering the cost of development and increasing the safety of the market.

LIMITATIONS AND CHALLENGES OF PHARMACOGENOMICS IN CANCER THERAPY

1. High Cost and Limited Accessibility: Genomic testing, sequencing, and bioinformatics analysis are the primary operations that draw the huge cost attached to pharmacogenomics. Most health systems, especially in developing countries, are unable to offer pharmacogenomic screening routinely. So the limited access continues to be a barrier to the wide use of personalized cancer therapy, therefore denying a lot of patients the opportunity to avail of custom treatments.[44]

2. Complexity of Cancer Genomics: Cancer is a genetically diverse disease with a variety of mutations, changes in the number of chromosomes, epigenetic modifications, and tumor heterogeneity as the disease progresses. All these things make it difficult to interpret pharmacogenomic data. The testing of one gene may not be enough to completely predict the drug response, and the heterogeneity of tumors may lead to different outcome in therapy, thus the precision of pharmacogenomic therapy is reduced.

3. Limited Clinical Evidence and Guidelines: Although pharmacogenomics was able to showcase its potential, the ground laboratory evidence for numerous biomarkers still remains inadequate. The FDA has given approval or recommendation backed by guidelines to only a few gene-drug pairs. The absence of uniform guidelines and consensus protocols adds to the confusion of the clinicians who have to decide whether to use pharmacogenomics or not in their oncology practices on a routine basis.

4. Ethical, Legal, and Privacy Concerns: Testing along the lines of pharmacogenomics entails ethics and law problems, e.g. patient consent, data privacy, and genetic discrimination. The process of storing and sharing genetic information for clinical decision-making has to strictly adhere to regulations. Furthermore, patients can be worried that the genetic data may affect their insurance coverage or employment, which can result in testing not being widely accepted.

5. Integration into Clinical Workflow: The process of implementing the pharmacogenomics in clinical practice is not without its challenges, one of which is the integration with electronic medical records, decision-support systems, and multidisciplinary teams. A lot of institutions do not have the required infrastructure, trained staff, or bioinformatics support. Without the proper integration, it will be possible that the pharmacogenomic information is either not used at all or incorrectly used, and hence its clinical impact will be diminished.[45]

FUTURE DIRECTIONS IN PERSONALIZED CANCER THERAPY

Integration of Multi-Omics Approaches: The usage of multi-omics technologies, such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, will be the future of personalized cancer therapy. The combination of these different levels of molecular information can lead to a comprehensive understanding of tumor biology, the discovery of novel therapeutic targets, and the improving of patient stratification. The multi-omics approaches not only allow clinicians to customize therapy more accurately but also to foresee the coming of resistance mechanisms.

Artificial Intelligence and Predictive Modeling: AI, ML, and computational modeling are majorly impacting precision oncology. AI is capable of processing the complexities of pharmacogenomics and the various layers of omics to foretell drug response, toxicity, and the best combination therapy. Predictive modeling is the backbone of individualized treatment planning, speeds up biomarker discovery, and assists clinicians in making real-time decisions that positively affect efficacy and adversely affect events.[46]

Liquid Biopsies and Real-Time Monitoring: ctDNA, CTCs, and exosomal biomarkers facilitate the minimally invasive and immediate monitoring of the tumor evolution. This, in turn, allows for the dynamic therapy adjustment based on either the newly discovered mutations or the resistance mechanisms, thus cutting down the need for the invasive biopsies being performed repetitively. Pharmacogenomics along with the liquid biopsy data grants the adaptive, personalized treatment all through the cancer journey.

Expanding Immunogenomics and Combination Therapies: The continuous progress in

immunogenomics and pharmacogenomics will boost the personalization of immunotherapy. The identification of distinct neoantigen tumor profiles, HLA genotypes and immune checkpoint variations will enable the tailor-made immune-based treatments for the patients. Subsequently, combining strategies like immunotherapy with targeted therapy or chemotherapy could be implemented accurately with the help of pharmacogenomic knowledge to reap full benefits and cause less harm at the same time.[47]

Gene Editing and Cell-Based Therapies: CRISPR/Cas9 and other gene-editing technologies are opening new frontiers for granting precise modifications to either tumor or immune cells, thus enabling therapy enhancement and resistance overcoming. Pharmacogenomics can pinpoint the patients who are most likely to reap the benefits from such specialized T-cell therapies, CAR-T cells, or gene-modified immune cells, thereby, mingling the personalized techniques with the state-of-the-art cellular therapies.

Global Implementation and Accessibility: One of the future paths is to make pharmacogenomic-informed personalized therapy available for everyone all over the world. Economical sequencing systems and appliances, integration of decision-aid tools into clinical practices, and training of clinicians and patients would be fundamental for pharmacogenomics-based personalized therapies going mainstream. The opening up of access will result in the sharing of precision oncology to a larger patient group, which will ultimately help in lessening the inequalities in cancer care.[48]

CONCLUSION

Pharmacogenomics has gained a reputation as the key element in personalized cancer therapy, and it has made the treatment strategies devised based on individual genetic profiles and the characteristics of the tumors possible. Clinicians, by adding genomic biomarkers to the clinical decision-making process, can optimize chemotherapy, targeted therapy, hormonal therapy, and immunotherapy, thus increasing efficacy and at the same time decreasing toxicity. And though there are challenges such as cost, tumor heterogeneity, and limited standardization, still, the progress in multi-omics, artificial intelligence, and real-time monitoring is very much widening the scope of precision oncology. The partnership of research, technological innovation, and clinical integration will ensure that the pharmacogenomics remains ever more so the case that it is a primary tool being used in the care of cancer patients that are kept at the forefront, and as such it will turn the tide in the battle against cancer by increasing both survival rates and the quality of life.

REFERENCES

1. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res, 2008 Sep; 25(9): 2097-116.
2. W. Haenszel and M. Kurihara. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst, 1968; 40: 43–68.
3. Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals (Basel). 2024 Jul 13; 17(7): 940.
4. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med. 2006; 57: 119–137.
5. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Pérez de la Lastra JM. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022 Mar 18; 10(4): 1367-1401.
6. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell. 2012 Feb 3; 148(3): 409-20.
7. Molla G, Bitew M. The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted Therapies. *Journal of Molecular Pathology*. 2025; 6(3): 20.
8. Hlaváč V, Holý P, Souček P. Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450. *Journal of Personalized Medicine*. 2020; 10(3): 108.
9. Gummadi AC, Guddati AK. Genetic Polymorphisms in Pharmaceuticals and Chemotherapy. World J Oncol. 2021 Oct; 12(5): 149-154.
10. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014 Feb; 171(3): 580-94.
11. Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, Chen ZS. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023 May 22; 4(3): e265.
12. Barbarino J.M., Whirl-Carrillo M., Altman R.B., Klein T.E. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip. Rev. Syst. Biol. Med. 2018; 10: e1417.
13. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, Thakare RP, Banday S, Mishra AK, Das G, Malonia SK. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel). 2023 Jul 13; 12(7): 997.
14. Bartha Á, Győrffy B. Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology. Cancers (Basel). 2019 Nov 4; 11(11): 1725.

15. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009 Jan; 10(1): 57-63.
16. Coyle KM, Boudreau JE, Marcato P. Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. Biomed Res Int. 2017; 2017: 9620870.
17. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010 Jan; 1805(1): 105-17.
18. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev. 2023 Jul; 75(4): 789-814.
19. Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer. 2011 Jan; 30(1): 5-12.
20. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020 Dec; 10(12): 1808-1825.
21. Mhandire DZ, Goey AKL. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients. Mol Diagn Ther. 2022 Mar; 26(2): 137-151.
22. Li J, Bluth MH. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med. 2011; 4: 11-33.
23. Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V, Ranga V, Sharma NK, Kumar A, Maurya PK, Maciaczyk J, Schmidt-Wolf IGH, Sharma A. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm (2020). 2024 May 31; 5(6): e582.
24. Li T, Chen Y, Li S. The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems. Int J Nanomedicine. 2024 Oct 19; 19: 10623-10637.
25. Delaney C, Frank S, Huang RS. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer. 2015 Apr 8; 34(4): 149-60.
26. Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, Lintas C, Tabolacci C. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel). 2023 Aug 8; 15(16): 4026.
27. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014: 852748.
28. Vargas-Castellanos E, Rincón-Riveros A. Microsatellite Instability in the Tumor Microenvironment: The Role of Inflammation and the Microbiome. Cancer Med. 2025 Apr; 14(8): e70603.
29. Varughese LA, Lau-Min KS, Cambareri C, Damjanov N, Massa R, Reddy N, Oyer R, Teitelbaum U, Tuteja S. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. Pharmacotherapy. 2020 Nov; 40(11): 1108-1129.
30. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018 Sep-Dec; 6(3-4): 79-100.
31. Franczyk B, Rysz J, Gluba-Brzózka A. Pharmacogenetics of Drugs Used in the Treatment of Cancers. Genes (Basel). 2022 Feb 7; 13(2): 311.
32. Truesdell P, Chang J, Coto Villa D, Dai M, Zhao Y, McIlwain R, Young S, Hiley S, Craig AW, Babak T. Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomes. NPJ Precis Oncol. 2024 Aug 28; 8(1): 186.
33. AlDoughaim M, AlSuhebany N, AlZahrani M, AlQahtani T, AlGhamdi S, Badreldin H, Al Alshaykh H. Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations. Clin Med Insights Oncol. 2024 Nov 17; 18: 11795549241298541.
34. Ling SP, Ming LC, Dhaliwal JS, Gupta M, Ardianto C, Goh KW, Hussain Z, Shafqat N. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Cancers (Basel). 2022 Oct 24; 14(21): 5205.
35. Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019; 15(5): 1111-1122.
36. Ulm M, Ramesh AV, McNamara KM, Ponnusamy S, Sasano H, Narayanan R. Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocr Connect. 2019 Feb 1; 8(2): R10-R26.
37. Bayala B, Zoure AA, Baron S, de Joussineau C, Simpore J, Lobaccaro J-MA. Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives. *International Journal of Molecular Sciences*. 2020; 21(10): 3690.
38. Maciejko L, Smalley M & Goldman A Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches. J. Mol. Biomark. Diagn, 2017; 8.
39. Verma M Personalized medicine and cancer. J. Pers. Med, 2012; 2: 1–14.
40. Duarte TT & Spencer CT Personalized proteomics: The future of precision medicine. Proteomes, 2016; 4.
41. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1): 42-55.

42. Saugstad AA, Petry N, Hajek C. Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. Front Genet, 2022 May 24; 13: 857120.
43. Peck R, Smith P. Beyond Genetics—Stratified and Personalised Medicines Using Multiple Parameters. *Pharmaceuticals*, 2010; 3(5): 1637-1651.
44. Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, D'Amico P, Duso BA, Curigliano G. Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist, 2019 Mar 19; 2(1): 43-52.
45. Arbitrio M, Milano M, Lucibello M, Altomare E, Staropoli N, Tassone P, Tagliaferri P, Cannataro M, Agapito G. Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis. Front Pharmacol, 2025 Apr 11; 16: 1548991.
46. Menyhárt O, Győrffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J., 2021 Jan 22; 19: 949-960.
47. Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V. Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation. Explor Target Antitumor Ther. 2025 Apr 27; 6: 1002313.
48. Feng X, Li Z, Liu Y, Chen D, Zhou Z. CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Exp Hematol Oncol. 2024 Oct 19; 13(1): 102.